Phagelux Overview

  • Founded
  • 2014
  • Status
  • Private
  • Employees
  • 5
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $10M
Latest Deal Amount
  • Investors
  • 2

Phagelux General Information


Developer of bacteriophages designed to provide alternatives to antibiotics for multiple fields. The company offers anti-bacterial products across multiple fields utilizing various phage and phage-based technologies, enabling users solve the bacterial problem and provide treatments to various diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 12th Floor, Huasheng Building
  • 398 Hankou Road, Huangpu District
  • Shanghai, 200001
  • China
+86 021 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Phagelux Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 09-Jun-2015 $10M 0000 Completed Startup
1. Seed Round 06-Mar-2014 Completed Startup
To view Phagelux’s complete valuation and funding history, request access »

Phagelux Patents

Phagelux Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9993532-B2 Broad spectrum of streptococcus lyase and use thereof Active 13-Apr-2015 000000000
CA-2981996-A1 Broad spectrum of streptococcus lyase and use thereof Pending 13-Apr-2015 000000000
US-20180104316-A1 Broad spectrum of streptococcus lyase and use thereof Granted 13-Apr-2015 000000000
EP-3312275-A4 Broad spectrum of streptococcus lyase and use thereof Pending 13-Apr-2015 000000000 0
EP-3312275-A1 Broad spectrum of streptococcus lyase and use thereof Pending 13-Apr-2015 A61K38/51
To view Phagelux’s complete patent history, request access »

Phagelux Executive Team (5)

Name Title Board Seat Contact Info
Mark Engel Board Member, Founder & Chief Executive Officer
William Wang Chief Operating Officer
Joey Zhou Director, Business Development
Rosemonde Mandeville Ph.D CSO
You’re viewing 4 of 5 executive team members. Get the full list »

Phagelux Board Members (3)

Name Representing Role Since
Edward Hu Ph.D Self Board Member 000 0000
Ge Li Ph.D WuXi Healthcare Ventures Board Member 000 0000
Mark Engel Phagelux Board Member, Founder & Chief Executive Officer 000 0000
To view Phagelux’s complete board members history, request access »

Phagelux Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Phagelux Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fosun Pharma Corporation Minority 000 0000 000000 0
WuXi Healthcare Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view Phagelux’s complete investors history, request access »

Phagelux Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 00000 15-Mar-2021 00000 0000 00.000 Biotechnology
00000000 0000 14-Oct-2015 0000000000 Biotechnology 0000000 0
0000000000 20-Jul-2015 0000000000 Multi-line Chemicals 0000 0000
Iveria Technologies (Novel Delivery Systems) 23-Dec-2014 Merger/Acquisition Drug Delivery
To view Phagelux’s complete investments and acquisitions history, request access »

Phagelux Subsidiaries (1)

Company Name Industry Location Founded
0000000000 Multi-line Chemicals Sandy, UT 0000
To view Phagelux’s complete subsidiaries history, request access »